Physician profile
Joel E Anhalt
NPI 1073623252
$6,463.83
in general payments reported to CMS, 2019-2025
30 companies · $848 in 2025
The $848 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $971 · 2021: $908 · 2022: $1,097 · 2023: $797 · 2024: $861 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.21 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $802.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $749.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $677.69 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $647.40 | 2021-2025 | Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $537.22 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $438.32 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $369.15 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $277.11 | 2020-2025 | Jardiance, Zepbound, Emgality |
| Pfizer INC. | $257.36 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $227.99 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $204.36 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $178.05 | 2019-2022 | |
| Exact Sciences Corporation | $142.24 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $128.16 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $117.93 | 2022-2025 | Eliquis, Camzyos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $112.56 | 2019-2021 | |
| Inspire Medical Systems, INC. | $110.63 | 2025 | Inspire |
| Dexcom, INC. | $93.20 | 2021-2022 | |
| Amarin Pharma, INC. | $67.89 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.30 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $66.53 | 2019-2020 | |
| Indivior INC. | $40.68 | 2020-2024 | Sublocade |
| Ironshore Pharmaceuticals INC. | $32.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.70 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.39 | 2024 | Ajovy |
| Abbott Laboratories | $15.97 | 2022 | |
| Resmed Corp | $15.66 | 2019 | |
| Lundbeck LLC | $14.17 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.06 | 2021 | |
| Allergan, INC. | $13.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Anhalt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.